MELBOURNE, Australia, and Princeton, N.J., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that sozinibercept will be highlighted during the Innovate Retina Meeting on October 17, 2024, in Chicago, Illinois.

David Boyer, MD, will present an update on Opthea’s wet AMD program, including highlights of the unmet medical need in wet AMD, the sozinibercept Phase 2b trial results, and the Phase 3 program designed to assess superiority in visual acuity of the combination therapy with sozinibercept over anti-VEGF-A monotherapy.

Details are as follows:

Session 4: New Routes and New Molecules
Timing: Thursday, October 17, 2024, 5:27 PM CT
Presentation: Update on OPT-302 (sozinibercept)
Presenter: David S. Boyer, MD
Agenda: https://retinainnovate.com/agenda/

Innovate Retina focuses exclusively on game-changing innovations in medical and surgical retina care, including current management of age-related macular degeneration (AMD) and diabetic retinopathy, ocular imaging, gene therapy, ocular inflammation, surgical technologies, ocular oncology, and the latest advances in retinal pharmacotherapy.

About Opthea

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve the overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.

To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn.

Authorized for release to ASX by Frederic Guerard, CEO

Investor Inquiries

PJ Kelleher 
LifeSci Advisors, LLC 
Email: [email protected]
Phone: 617-430-7579

Media Inquiries

Silvana Guerci-Lena 
NorthStream Global Partners 
Email: [email protected]

Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399, Email: [email protected] Web: www.opthea.com

Source: Opthea Limited